BD Reports Second Quarter Fiscal 2026 Financial Results
BD announced its fiscal 2026 second quarter results, highlighting revenue growth, improved margins, and an increase in adjusted EPS guidance. The company attributes strong performance to broad-based execution across its segments. Following a recent spin-off of its Biosciences and Diagnostic Solutions business, BD confirmed disciplined execution of its New BD strategy focusing on innovation and capital allocation.
Revenue of $4.7 billion increased 5.2% as reported, 2.6% FXN GAAP and adjusted diluted EPS from continuing operations of $(0.13) and $2.90, respectively Executed a $2.0 billion accelerated share repurchase (ASR) program and retired $2.1 billion of debt in the quarter Company reaffirms…